Actively Recruiting
Comparing DSP107 with Atezolizumab Versus Fruquintinib for Advanced Microsatellite Stable Colorectal Cancer A Randomized Phase 2b Study
Led by Kahr Bio Australia Pty Ltd · Updated on 2026-08-20
90
Participants Needed
18
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new combination of medicines, DSP107 and atezolizumab, compared to an existing treatment, fruquintinib, for adults with advanced microsatellite stable MSS colorectal cancer. This Phase 2b study focuses on patients whose cancer has progressed or who cannot tolerate standard therapies. The study aims to assess whether the new combination improves patient outcomes while monitoring safety and how the body processes these treatments. Participants will be randomly assigned to one of two groups. One group receives DSP107 intravenously on Days 1, 8, and 15, plus atezolizumab intravenously on Day 1 of each 28-day cycle. The other group takes fruquintinib orally once daily for 21 days, followed by 7 days off, in 28-day cycles. The treatment period can last up to 24 cycles, with adjustments made based on tolerance. After treatment, a safety follow-up of up to 90 days will occur, followed by long-term follow-up for up to five years. During the study, participants will have regular assessments including evaluations of overall survival, adverse events, heart function via ECG, blood pressure, pulse rate, quality of life, and immune response to DSP107. Participants keep dosing diaries if taking fruquintinib. The study includes screening lasting up to 28 days before treatment starts. Total participation time depends on treatment response and tolerability, with ongoing monitoring throughout and after the treatment phase.
CONDITIONS
Brief Title
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Research Team
A
Adam Foley Comer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here